Clearside Biomedical

Clearside Biomedical Total Assets

Delisted

The Total Assets of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 25.13 M USD. In the previous year, Total Assets was 34.02 M USD — a change of -26.14% (lower).

Total Assets

25.13 MUSD

YoY

-26.14%

Last updated:

Total Assets of Clearside Biomedical is 2024 25.13 M USD. Total Assets of Clearside Biomedical was 2023 34.02 M USD. It decreases by -26.14% lower compared to the previous year.

The Clearside Biomedical Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2017
40.49 M USD
Jan 1, 2018
44.12 M USD
Jan 1, 2019
26.78 M USD
Jan 1, 2020
19.32 M USD
Jan 1, 2021
42.90 M USD
Jan 1, 2022
51.30 M USD
Jan 1, 2023
34.02 M USD
Jan 1, 2024
25.13 M USD
The Clearside Biomedical Total Assets history
YEARTotal AssetsYoY
25.13 MUSD-26.14%
34.02 MUSD-33.69%
51.30 MUSD+19.58%
42.90 MUSD+122.05%
19.32 MUSD-27.86%
26.78 MUSD-39.30%
44.12 MUSD+8.97%
40.49 MUSD-52.26%
84.81 MUSD+302.71%
21.06 MUSD+104.47%
10.30 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Total Assets of Clearside Biomedical is 25.13 M USD in 2024.

Total Assets of Clearside Biomedical changed from 34.02 M USD to 25.13 M USD, representing a -26.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clearside Biomedical

All Key Metrics — Clearside Biomedical